Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

After a joint injury, around 50% of people will go on to develop premature osteoarthritis. Chief investigator Dr Fiona Watt says: “Following the 150 participants in KICK over the next five years will help us to understand why a joint injury leads to osteoarthritis in some individuals, but not others. This will allow us to develop tests which identify those at greatest risk. We hope that this will ultimately enable us to intervene in key pathways following a joint injury to prevent this disabling condition”.

Other work in the Kennedy Institute has identified specific markers of inflammation following injury; KICK aims to determine whether it is possible to predict the development of osteoarthritis from this initial molecular response of the joint to the injury. The study also hopes to identify novel targets for preventing or treating early disease.

KICK is run at The Arthritis Research UK Centre for Osteoarthritis Pathogenesis, based in the Kennedy Institute of Rheumatology, at Oxford, and benefits from a range of collaborations, namely with Andrew Williams, leading UK sports knee surgeon working at Fortius Clinic, London. Commenting on the recent milestone, he said: “This is a great achievement. Understanding the key detrimental humoral 'players' that lead to osteoarthritis will open the possibility of providing therapies to prevent development of osteoarthritis after trauma which is especially prevalent in the young and increasingly so. The need for this is one of the most pressing goals in medicine today.”

KICK is funded by the Kennedy Trust for Rheumatology Research, with additional infrastructure support from Arthritis Research UK.

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology


The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Drug may boost vaccine responses in older adults

General Research

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research


In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

3D imaging reveals the role of blood vessels in hormone production


New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.

Wellcome funding awarded to Oxford team to support research into heart muscle regeneration

Awards Research

An Oxford team from the Centre for Medicines Development, Department of Physiology Anatomy and Genetics and Radcliffe Department of Medicine led by Professor Jagdeep Nanchahal at the Kennedy Institute has been awarded a Wellcome Innovator Award to develop a first in class therapeutic aimed at regenerating heart muscle after heart attack.

An unexpected repair function for neutrophils


In a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.